Geron (NASDAQ:GERN) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Geron (NASDAQ:GERN) released its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05, Briefing.com reports. The firm had revenue of $28.27 million for the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. The firm’s revenue for the quarter was up 17138.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.08) earnings per share.

Geron Trading Down 0.9 %

Shares of Geron stock traded down $0.04 on Friday, reaching $4.25. 12,134,583 shares of the company were exchanged, compared to its average volume of 10,462,797. The stock has a fifty day moving average price of $4.32 and a 200-day moving average price of $4.30. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of -13.28 and a beta of 0.52. The company has a current ratio of 3.61, a quick ratio of 3.60 and a debt-to-equity ratio of 0.12. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34.

Analyst Upgrades and Downgrades

GERN has been the topic of a number of research reports. Leerink Partnrs upgraded Geron to a “strong-buy” rating in a report on Monday, September 9th. Wedbush reiterated an “outperform” rating and set a $8.00 target price on shares of Geron in a report on Thursday, August 8th. Scotiabank started coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price objective on the stock. StockNews.com upgraded Geron to a “sell” rating in a report on Monday, August 5th. Finally, HC Wainwright started coverage on Geron in a report on Tuesday. They set a “buy” rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Geron presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.05.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.